{"id":213697,"name":"HIKMA PHARMACEUTICALS USA INC.","slug":"hikma-pharmaceuticals-usa-inc","state":"NJ","country":"United States of America","description":"Pharmaceutical manufacturer","totalSpending":570000,"filings":17,"yearlySpending":[{"year":2022,"income":100000},{"year":2023,"income":200000},{"year":2024,"income":110000},{"year":2025,"income":160000}],"issues":["HCR","TRD"],"firms":["APCO WORLDWIDE LLC"],"lobbyists":["ALLISON PARKER-LAGOO","DAN SCANDLING","MIKASA MODI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Food & Drug Administration (FDA)","White House Office","Drug Enforcement Administration (DEA)","Office of Natl Drug Control Policy (NDCP)","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","Commerce, Dept of (DOC)","U.S. Trade Representative (USTR)","Office of Management & Budget (OMB)"],"sampleDescriptions":["Health and pharmaceutical policies before the Congress and the Administration","Health and pharmaceutical policies before the Congress and the Administration. S. 3799, Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act, all provisions related to ","Health and pharmaceutical policies before the Congress. S. 4348, FDASLA Act of 2022, all provisions related to fees related to generic drugs.","Health and pharmaceutical policies and domestic pharmaceutical manufacturing supply chain issues before the Congress.","Health and pharmaceutical policies and domestic pharmaceutical manufacturing supply chain issues before the Congress."],"years":[2022,2023,2024,2025]}